ABCC2 Gene Polymorphism Analysis for QT Prolongation Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict and manage the predisposition of individuals to QT interval prolongation, which can be induced by certain compounds, leading to potential long QT syndrome (LQTS) due to the lack of genetic analysis for ABCC2 gene polymorphisms.
Innovation Solution
Determining the ABCC2 gene sequence or its expression products in individuals to assess the risk of QT prolongation and adjusting the dosage or selecting alternative compounds that do not prolong the QT interval, based on specific genotypes or expression profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic analysis of ABCC2 gene polymorphisms is performed to predict QT prolongation predisposition, then prediction accuracy is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The diagnostic process is segmented into distinct stages: initial risk assessment using simple clinical criteria, followed by selective genetic testing of specific ABCC2 gene polymorphisms (such as rs2273697 and rs7067971) only for patients who meet certain risk thresholds. This segmentation allows the system to achieve high prediction accuracy through targeted genetic analysis while avoiding the complexity and cost of universal genetic screening.
Solution Approach 2:
The patent implements preliminary risk stratification using non-invasive clinical parameters (demographics, medical history, medication profiles) before proceeding to genetic testing. This preliminary action identifies a subset of patients who would benefit most from genetic analysis, thereby improving overall prediction accuracy while minimizing the number of complex genetic tests performed in the population.
2Reliability
If ABCC2 gene sequencing is performed on all patients before QT-prolonging compound administration, then patient safety is improved, but treatment time and cost increase
Solution Approach 1:
The patent applies genetic testing selectively to specific patient populations based on their local characteristics - namely, patients who are prescribed QT-prolonging compounds and meet predefined risk criteria. Rather than universal testing, the system tailors the depth of genetic analysis to the specific risk profile of each patient group, achieving enhanced safety for high-risk patients while avoiding unnecessary testing in low-risk populations.
Solution Approach 2:
The patent implements a tiered testing strategy where only the most clinically relevant ABCC2 polymorphisms are tested initially (partial action), rather than complete genomic sequencing. This approach provides sufficient safety information for clinical decision-making in the majority of cases while significantly reducing testing time and cost. Full sequencing is reserved for cases where partial testing yields inconclusive results or where clinical suspicion remains high.
3Object-affected harmful factors
If dosage is reduced or alternative compounds are selected for patients with ABCC2 polymorphisms, then risk of QT prolongation is reduced, but treatment efficacy may be compromised
Solution Approach 1:
The patent implements dynamic treatment adjustment based on genetic test results. Rather than static dosing protocols, the system enables real-time modification of treatment plans according to the patient's ABCC2 genotype. For patients with high-risk polymorphisms, the system dynamically selects alternative compounds or adjusts dosing schedules to minimize QT prolongation risk while maintaining therapeutic efficacy through close monitoring and flexible protocol adjustment.
Solution Approach 2:
The patent incorporates feedback loops where patients with ABCC2 polymorphisms receive enhanced monitoring of their QT intervals and clinical responses. This feedback mechanism allows clinicians to observe actual treatment outcomes and adjust dosing or switch compounds based on real-world performance data, ensuring that treatment efficacy is maintained while managing QT risk. The system learns from each patient's response to optimize future treatment decisions.
Data Source
AI summary
The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.